Nielsen joins Catalent as chief technology officer

Catalent Pharma Solutions has appointed Kurt Nielsen as chief technology officer and senior vice president of innovation and growth.

Catalent Pharma Solutions has appointed Kurt Nielsen as chief technology officer and senior vice president of innovation and growth.

Nielsen will drive innovation activities and investments across Catalent's range of advanced dose forms and packaging technologies. He will be based in Catalent's global headquarters in Somerset, NJ, US.

Nielsen most recently served as executive vice president of pharmaceuticals for URLMutual Pharmaceutical Company, where he led new product development and licensing activities for both products and drug delivery technologies, as well as the division's manufacturing and quality operations.

Nielsen has also held r&d leadership positions with Teva Pharmaceuticals US and the McNeil Consumer Products division of Johnson & Johnson. He has a PhD in chemistry from Villanova University and a BSc in chemistry from the University of Delaware.

You may also like

Manufacturing

Catalent begins $20 million construction project

The project creates space in the original building to accommodate the installation of a new, fully automatic bottle filling line
Manufacturing

Catalent increases packaging capabilities at Philadelphia facility

Validation of the equipment is planned to be completed by the end of Q1 2022
Packaging

Catalent and Stirling Ultracold partner on energy-efficient cold chains

The company has agreed to use Stirling's ULT freezers that use 100% natural refrigerants and around 30% of the carbon dioxide during operation compared with legacy ULT freezers
Manufacturing

Catalent acquires Acorda manufacturing and packaging operations

Completion of the transaction is subject to customary closing conditions and is expected to occur in the first quarter of this calendar year
Packaging

Catalent Biologics completes $14m medicine packaging expansion

US-based Catalent has completed a 15,000 sqft expansion at its Bloomington, Indiana facility
Manufacturing

Expanded access and commercial packaging for niche-market drugs

Securing timely and reliable commercial packaging services can be challenging for orphan, niche and other low-volume drugs because of their need to compete against high-volume drugs for access to the limited and often preallocated production capacity available at contract packaging facilities. Catalent's Karl Jones and Matthew Stark report
Packaging

Catalent to open new clinical supply centre in the US

The facility in San Diego is due to open in the summer of 2020
Subscribe now